The outcome for patients with metastatic rhabdomyosarcoma (RMS) remains poor. A previous Children's Oncology Group (COG) study (ARST0431) for patients with metastatic RMS produced no improvement in outcome using multiple cytotoxic agents in a dose-intensive manner. The authors report results from the subsequent COG study (ARST08P1), which evaluated the feasibility and efficacy of adding cixutumumab (insulin-like growth factor-1 monoclonal antibody) or temozolomide to the ARST0431 intensive chemotherapy backbone. METHODS: Two nonrandomized pilot studies were conducted in patients with metastatic RMS, initially to determine feasibility, and both pilots were expanded to assess efficacy. All patients received 54 weeks of chemotherapy, including vincristine/irinotecan, interval-compressed vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide, and vincristine/dactinomycin/cyclophosphamide. In pilot 1, patients received intravenous cixutumumab (3, 6, or 9 mg/kg) once weekly throughout therapy. In pilot 2, patients received oral temozolomide (100 mg/m 2 ) daily for 5 days with irinotecan. All patients received radiation to the primary tumor and to metastatic sites. RESULTS: One hundred sixty-eight eligible patients were enrolled (97 on pilot 1 and 71 on pilot 2). Most patients were aged ≥10 years (73%), with alveolar histology (70%), and had bone and/or bone marrow metastases (59%). Toxicities observed in each pilot were similar to those reported on ARST0431. With a median follow-up of 2.9 years, the 3-year event-free survival rate was 16% (95% confidence interval, 7%-25%) with cixutumumab and 18% (95% confidence interval, 2%-35%) with temozolomide. CONCLUSIONS: The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy for metastatic RMS was safe and feasible. Neither agent improved outcome compared with the same chemotherapy that was used on ARST0431. Cancer 2019;125:290-297.
INTRODUCTION
Approximately 15% of patients with rhabdomyosarcoma (RMS) have distant metastases at diagnosis. 1 Whereas most patients who have localized disease can be cured, the outcome for those who have metastatic RMS is poor and has not improved over the past several decades. [1] [2] [3] [4] Although small subsets of patients with metastatic RMS have a more favorable outcome, 5 long-term event-free survival (EFS) for patients with metastatic RMS is less than 20%. [5] [6] [7] A recent Children's Oncology Group (COG) study, COG ARST0431, 7 evaluated an intensive chemotherapy regimen using the most active agents identified from previous phase 2 window studies. 8 The ARST0431 regimen included 6 weeks of initial therapy with vincristine and irinotecan (VI); followed by interval-compressed cycles of vincristine, doxorubicin, and cyclophosphamide (VDC) alternating with ifosfamide and etoposide (IE); 2 subsequent courses of VI with radiation therapy to primary and metastatic sites; and 4 cycles of vincristine, dactinomycin and cyclophosphamide
Cancer January 15, 2019 (VAC). Although the early EFS results were encouraging, 9 more mature 3-year EFS was 38% for all patients but was only 20% for those who had more than 1 risk factor as defined by Oberlin et al (age >10 years or <1 year, unfavorable primary site, 3 or more metastatic sites, and bone or bone marrow involvement). 5, 7 Hence, intensification of traditional treatment modalities did not improve outcome for the majority of patients with metastatic RMS.
Although prognosis is significantly better for patients with localized RMS, outcome has not improved in recent years despite the evaluation of additional cytotoxic agents. 3, 10 Therefore, novel treatment strategies are needed for both localized and metastatic RMS. Evaluating new agents added to an established chemotherapy backbone in patients with metastatic RMS may help to identify therapies that are worthy of further study in patients with localized RMS while also determining whether these agents may be safe and effective for patients with metastatic disease.
The insulin-like growth factor-1 receptor (IGF-1R) is a potentially important therapeutic target for RMS. 11, 12 It is highly expressed in RMS and appears to be involved in the initiation and progression of the disease. 11, 13 Cixutumumab (IMC-A12) is a human IgG1/ monoclonal antibody against the IGF-1R that has exhibited strong in vitro and in vivo activity against RMS. 14, 15 Cixutumumab has been evaluated in pediatric single-agent phase 1 and 2 studies, 16, 17 but the addition of cixutumumab to a multiagent chemotherapy backbone has not previously been studied in pediatric patients or in patients with RMS.
Alkylating agents like cyclophosphamide and ifosfamide are highly active in RMS and are a component of therapy for intermediate-risk and high-risk disease. Temozolomide is an alkylating agent that has demonstrated synergy with irinotecan in preclinical models of pediatric solid tumors 18 and is active when combined with irinotecan in patients with neuroblastoma and pediatric sarcomas. [19] [20] [21] The addition of temozolomide to irinotecan for patients with previously untreated metastatic RMS has not previously been evaluated.
Here, we report the results of the COG study ARST08P1, which included 2 pilot studies to evaluate the addition of cixutumumab or temozolomide to an intensive multiagent chemotherapy backbone for the treatment of metastatic RMS. The primary objective of COG ARST08P1 was to evaluate the feasibility of combining cixutumumab or temozolomide with the chemotherapy regimen used in the predecessor study, COG ARST0431. An additional objective was to assess the efficacy of adding cixutumumab or temozolomide to the chemotherapy backbone.
MATERIALS AND METHODS

Eligibility
Patients aged <50 years who had with newly diagnosed RMS metastatic at sites other than regional lymph nodes were eligible. To establish safety of the combination regimens, we initially excluded patients aged <10 years with metastatic embryonal RMS (ERMS), who have more favorable outcomes. After the initial 110 patients were enrolled and study treatment was determined to be safe and feasible, eligibility was expanded to all patients aged <50 years with metastatic RMS regardless of histology. Patients had adequate renal, liver, and cardiac function. Patients with uncontrolled infections or known diabetes mellitus as well as women who were pregnant or breastfeeding were excluded. All enrolled patients had a central pathology review of their tumors to confirm the diagnosis of RMS and to subclassify tumors into histologic types. The review was performed by 2 senior pediatric pathologists experienced in pediatric sarcoma diagnosis: subclassification was based on guidelines promulgated by the Intergroup Rhabdomyosarcoma Study. 22 The trial was reviewed and approved by the National Cancer Institute's Pediatric Central Institutional Review Board. Each participating COG institution also obtained approval from its local institutional review board. Informed consent was obtained from the patient or parent/guardian before enrollment, with patient assent when appropriate.
Study Design
The clinical trial consisted of 2 pilot studies, with block sequential enrollment of 20 patients, adding either cixutumumab (pilot 1) or temozolomide (pilot 2) to the backbone chemotherapy used in COG ARST0431. 7 Patients received 54 weeks of chemotherapy, beginning with 2 cycles of VI (weeks 1-6), followed by 6 cycles of alternating interval-compressed VDC and IE (weeks 7-19) (Supporting Table 1 ). VI cycles were repeated at weeks 20 through 25 and weeks 47 through 51. Intervalcompressed VDC/IE cycles were administered again at weeks 28 through 34 followed by 4 and neutrophil growth factor was received after VDC, IE, and VAC cycles. The initiation of each cycle of chemotherapy required an absolute neutrophil count ≥750/μL and a platelet count ≥75,000/μL.
Radiation therapy (50.4 Gy) to the primary tumor was received by most patients starting at week 20. Patients who required emergent radiation and those who had intracranial extension of parameningeal disease started receiving primary site radiation beginning at week 1. Radiation to metastatic sites was delivered at week 20 and/or week 47.
For patients on pilot 1, cixutumumab was delivered as a 1-hour intravenous infusion once weekly throughout treatment. If the start of a chemotherapy cycle was delayed because of myelosuppression, then cixutumumab was also held until blood count recovery. Cixutumumab also was held during radiation therapy. Doses of chemotherapy agents were adjusted for hyperbilirubinemia and sinusoidal obstruction syndrome; for any sinusoidal obstruction syndrome, cixutumumab was permanently discontinued. The cixutumumab dose was escalated in sequential cohorts of 3, 6, and 9 mg/kg (the pediatric phase 2 dose), with escalation dependent upon tolerability at the previous dose level. After enrollment of the initial 20 patients to each cixutumumab cohort, accrual to pilot 1 was suspended to monitor for toxicity. The subsequent 20 patients were enrolled on pilot 2, followed by the accrual of 20 patients to the next higher cixutumumab dose level (if the previous dose level was determined to be safe and tolerable). Patients on pilot 2 received oral temozolomide 100 mg/m 2 daily for 5 days with each VI cycle at weeks 1 through 6, 20 through 25, and 47 through 51.
Statistical Methods
The primary objective of this study was to assess the feasibility of adding each novel agent onto the chemotherapy backbone. Feasibility for pilot 1 was defined as a rate of serious cardiac toxicity (defined as grade ≥3 according to Common Terminology Criteria for Adverse Events, version 4) attributable to cixutumumab of ≤10%. For pilot 2, the addition of temozolomide was considered feasible if the rate of grade 4 nonhematologic toxicity throughout treatment was <15%. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria (version 4.0).
A secondary objective was to evaluate EFS and overall survival (OS) in patients who received treatment with each pilot regimen. EFS was defined as the time from enrollment to first progression, recurrence after initial response, second malignancy, or death. OS was defined as the time from enrollment to death from any cause. EFS and OS were estimated using the Kaplan-Meier method, 23 and comparisons were made between pilot studies using the log-rank test. We also analyzed EFS and OS for subsets based on previously defined risk factors in patients with metastatic RMS. Outcome was determined separately for patients with ERMS aged <10 years, ERMS aged ≥10 years, and alveolar RMS (ARMS). In addition, outcome was analyzed according to the number of risk factors, as defined by Oberlin et al: age (<1 or ≥10 years), unfavorable primary tumor site, bone or bone marrow metastases, and ≥3 metastatic sites. Note that histology is not included in this risk model. 5 Initial planned enrollment included expanding the more feasible and compelling pilot study to 75 patients to allow comparison with ARST0431. This provided Cancer January 15, 2019 approximately 80% power at the .01 significance level (1-sided) to detect an increase in EFS associated with a reduction in the risk of failure to 59% of that with ARST0431 therapy (corresponding to an EFS of 56% at 3 years). ARST08P1 was amended in September 2012 to address a limited supply of cixutumumab, which would no longer be available after March 2014. To ensure that any enrolled patient could complete therapy, a cutoff for enrollment on pilot 1 at the cixutumumab dose level of 9 mg/kg was established at 60 patients or until January 15, 2013 (whichever occurred earlier). Thereafter, enrollment to pilot 2 (temozolomide) was expanded to 75 patients.
RESULTS
One hundred sixty-eight eligible patients were enrolled on ARST08P1 between January 19, 2010 and July 19, 2013. Pilot 1 met its accrual goal in January 2013. Seven enrolled patients were identified as ineligible (3 who were assigned to cixutumumab, and 4 who were assigned to temozolomide). Five patients had ineligible histology on central review and were removed from protocol therapy. For 2 patients, initial staging was incorrect.
Among 97 eligible patients who received cixutumumab, 19 received a dose of 3 mg/kg, 18 received 6 mg/kg, and 60 received 9 mg/kg. Seventy-one eligible patients were enrolled on pilot 2 and received temozolomide. Table 1 lists the characteristics of eligible patients, which were similar between those who received cixutumumab and those who received temozolomide. Most patients had alveolar histology (70%), were age ≥10 years (73%), had primary tumors measuring ≥5 cm (80%), and had regional lymph node involvement (67%).
Toxicity
Grade 3 and higher nonhematologic toxicities are listed in Table 2 . The most commonly observed grade 3 or 4 toxicities on pilot 1 (cixutumumab) were febrile neutropenia (42%), diarrhea (36%), and hyperglycemia (26%). Four patients (4%) had grade 3 or 4 cardiotoxicity, which was below the 10% feasibility target. Three cases of severe hepatopathy were observed in the cohort that received cixutumumab at 9 mg/kg, 1 of which was fatal. The study was amended on May 31, 2013, to reduce cixutumumab to 6 mg/kg for all patients who initially were assigned to the 9 mg/kg cohort and were still receiving therapy, after which no further episodes of hepatopathy were observed. The most common grade 3 or higher toxicities that occurred on pilot 2 (temozolomide) were febrile neutropenia (46%) and infection (24%). The frequency and severity of toxicities with the addition of either cixutumumab or temozolomide were similar to those observed on ARST0431. 7 
Outcome
The median follow-up for all 168 eligible patients is 2.9 years. Estimated 3-year EFS and OS for all patients were 16% (95% confidence interval [CI], 8%-23%) and 41% (95% CI, 32%-50%), respectively. Patients who received temozolomide had statistically significantly poorer EFS (P = .0226) and OS (P = .0297) than those who received cixutumumab (Figs. 1 and 2) . The median time from enrollment to an event was 21.5 months with cixutumumab and 17.5 months with temozolomide. Three-year EFS and OS were 16% (95% CI, 7%-25%) and 47% (95% CI, 36%-58%), respectively, with cixutumumab (for all dose levels combined) and 18% (95% CI, 2%-35%) and 33% (95% CI, 18%-47%), respectively, with temozolomide. EFS according to cixutumumab dose level compared with temozolomide is detailed in Supporting Figure 1 .
Outcomes for subgroups defined by histology/age and Oberlin risk factors are provided in Table 3 . Patients with ARMS (3-year EFS, 6%) had worse outcomes than those with ERMS regardless of age. In addition, outcomes were worse for patients who had ≥2 Oberlin risk factors (3-year EFS, 9%). On both treatment arms, EFS and OS were better for patients with ERMS aged Cancer January 15, 2019 <10 years compared with older patients with ERMS and those with ARMS (Table 4) .
DISCUSSION
The treatment of metastatic RMS remains a significant challenge, because most of these patients are not cured. Several clinical trials over the past few decades have demonstrated no benefit from the intensification of cytotoxic therapy over standard VAC chemotherapy for metastatic RMS. 2, 7, 8, 24, 25 In addition, although outcomes have improved over time for patients with localized RMS, with improved staging, local control therapy, and supportive care, no systemic treatment has been proven superior to VAC alone. 10, 26 Because the limit of what can be achieved with traditional cytotoxic agents in the treatment of RMS likely has been reached, focus has shifted to identification of novel biologic agents with different mechanisms of action. The majority of patients with metastatic RMS have alveolar histology, the molecular hallmark of which is paired box 3 (PAX3) or PAX7 gene fusion with forkhead box protein O1 (FOXO1). Unfortunately, efforts to target PAX-FOXO1 fusion oncoproteins directly are not yet clinically viable. 27, 28 However, downstream pathways activated by PAX-FOXO1 may be amenable to targeted therapy.
One downstream effect of PAX-FOXO1 fusion is activation of the IGF-1R pathway. 11 In RMS, signaling through IGF-1R appears to promote resistance to cytotoxic therapy, and IGF-1R inhibition results in significant preclinical antitumor activity. 15, 29, 30 Therefore, although only limited single-agent activity was observed with the IGF-1R inhibitor cixutumumab in pediatric phase 1 and phase 2 studies, 16, 17 we hypothesized that the addition of cixutumumab to a multiagent chemotherapy backbone for metastatic RMS would be feasible and might improve outcome by enhancing the effects of cytotoxic therapy. By evaluating the activity of cixutumumab in patients with metastatic RMS, we also wanted to determine whether clinical evaluation of IGF-1R inhibition for localized RMS was warranted.
In the current study, the addition of cixutumumab to the intensive multiagent chemotherapy regimen used in ARST0431 proved to be feasible and had toxicity similar to that of the chemotherapy backbone alone. However, we did not observe an outcome benefit with the addition of this agent. Despite the dose de-escalation from 9 mg/kg to 6 mg/kg on this study, it is unlikely that the lack of efficacy was caused by insufficient cixutumumab drug levels. On the basis of pediatric phase 2 data and better target trough concentrations sufficient to inhibit IGF-1R, 31 the recommended phase 2 dose of cixutumumab in adults was 6 mg/kg based on the trough concentrations. Therefore, it is more likely that mechanisms of resistance to IGF-1R inhibition developed or were unmasked. Activation of pathways to overcome IGF-1R inhibition, such as human epidermal growth factor receptor 2, have been identified in models of RMS. 32 Future evaluation of IGF-1R inhibitors in RMS will require a better understanding of this and other mechanisms of resistance.
In our study, the 3-year EFS with cixutumumab (16%) and with temozolomide (18%) was inferior to the overall 3-year EFS of 38% on ARST0431. Although the observed EFS was poor on both pilot studies, survival outcomes for patients who received temozolomide were worse, with a shorter time to progression compared with patients who received cixutumumab (P = .023). Because patient characteristics and toxicity were similar between treatment arms, the reason for the shorter median time to progression with temozolomide is not known. Outcomes were similarly worse for patients with ARMS than for those with ERMS on both treatment arms.
Because the initial ARST08P1 eligibility criteria excluded patients with ERMS aged <10 years, the inferior 3-year EFS observed on this study compared with ARST0431 may be attributable at least in part to the lower percentage of such patients on ARST08P1 (12 of 168 on ARST08P1 vs 20 of 97 on ARST0431). The 3-year EFS rate of 64% for patients aged <10 years with ERMS observed on this study is concordant with outcomes for the same subset of patients on ARST0431. However, in the current study, the 38 patients who had <2 Oberlin risk factors had a 3-year EFS of 38%, which was inferior to that of 43 similar patients on ARST0431 (69%), despite their receipt of virtually identical backbone chemotherapy. Three-year EFS also was somewhat inferior among patients who had ≥2 Oberlin risk factors (n = 130; 9%) compared with that among patients on ARST0431 (n = 66; 20%). Although the addition of cixutumumab or temozolomide could have antagonized the backbone chemotherapy, firm explanations for the inferior EFS are elusive. Assessing whether the addition of either agent had an impact on dose intensity was not an objective of this trial and has not been analyzed.
Because of the lack an improvement in outcome with cixutumumab or temozolomide, we do not recommend either agent for the treatment of patients with newly diagnosed, metastatic RMS. Although the administration of cixutumumab in combination with chemotherapy was generally feasible, the rare but potentially life-threatening liver toxicity observed is a concern. Monitoring for liver toxicity will be important if cixutumumab is evaluated in combination with chemotherapy in future clinical trials. Because neither cixutumumab nor temozolomide improved outcomes, neither agent will be evaluated in the upfront setting for patients with localized RMS. In addition, because outcomes for the majority of patients with metastatic RMS who received the ARST0431 backbone were not superior to outcomes for those who received less intensive backbones, future studies for metastatic RMS will evaluate novel agents on a less intensive backbone, such as VAC or VAC/VI, and will explore the utility of early, novel endpoints (including early functional imaging responses) as part of smaller phase 2 screening or selection design studies to prioritize agents for testing in larger phase 3 studies. 1 
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